Related Experiment Videos
Targeted therapies for cancer 2004
Jeffrey S Ross1, David P Schenkein, Robert Pietrusko
1Department of Pathology and Laboratory Medicine, Albany Medical College, NY 12208, USA.
American Journal of Clinical Pathology
|October 19, 2004
Summary
Targeted cancer therapies and integrated diagnostics are revolutionizing oncology. Advances in molecular diagnostics and pharmacogenomics enable personalized cancer treatment and drug development.
Area of Science:
- Oncology
- Molecular Diagnostics
- Pharmacogenomics
Background:
- Recent approvals of targeted therapies like imatinib mesylate and cetuximab highlight a shift towards precision medicine in cancer treatment.
- The discovery of specific gene mutations predicting drug response, such as in non-small cell lung cancer treated with gefitinib, has accelerated interest in targeted anticancer drugs.
- The development of molecular diagnostics for hematologic malignancies and antibody-based therapies like trastuzumab for HER-2/neu overexpressing breast cancer exemplifies this progress.
Purpose of the Study:
- To review the history and evolution of targeted anticancer therapies.
- To highlight the role of molecular diagnostics in classifying and selecting cancer treatments.
- To explore the potential of pharmacogenomic strategies and genomic microarrays in revolutionizing cancer care.
Main Methods:
- Historical review of targeted anticancer therapies and molecular diagnostics.
- Discussion of specific examples of targeted drugs and their diagnostic markers.
- Consideration of pharmacogenomic strategies and genomic microarray applications.
Main Results:
- The emergence of targeted therapies integrated with diagnostics is creating a new era in cancer treatment.
- Molecular diagnostics are crucial for identifying patients likely to respond to specific targeted therapies.
- Pharmacogenomic strategies and genomic microarrays show promise for classifying cancer and guiding therapy selection.
Conclusions:
- Targeted anticancer therapies, driven by molecular diagnostics, are transforming cancer treatment paradigms.
- The integration of diagnostics and therapeutics is personalizing cancer care and drug development.
- Future advancements in molecular diagnostics and pharmacogenomics are expected to further revolutionize cancer drug discovery and clinical application within the next decade.